PARC report: health outcomes and value of personalized medicine interventions: impact on patient care

被引:5
|
作者
Mitropoulou, Christina [1 ]
Litinski, Veronika [2 ]
Kabakchiev, Boyko [2 ]
Rogers, Sara [3 ]
Patrinos, George P. [4 ,5 ,6 ]
机构
[1] Golden Helix Fdn, London WC2N 5AP, England
[2] GeneYouIn Inc, Toronto, ON M5B 2L7, Canada
[3] Amer Soc Pharmacovigilance, Houston, TX 77225 USA
[4] Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26504, Greece
[5] United Arab Emirates Univ, Dept Pathol, Coll Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Zayed Ctr Hlth Sci, Al Ain, U Arab Emirates
关键词
economic evaluation; insurance; personalized medicine; pharmacogenetic testing; pharmacogenetics; pharmacogenomics; precision medicine; pricing; reimbursement;
D O I
10.2217/pgs-2019-0194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, individualized clinical interventions that maximize efficacy and/or minimize the risk of adverse drug reactions. In order to ensure equal access to genomic testing for all patients, the costs associated with these interventions must be reimbursed by payers and insurance bodies. As such, it is of utmost importance to thoroughly evaluate these interventions both in terms of their clinical effectiveness and their economic cost. This article discusses the impact of personalized medicine interventions in terms of both health outcomes and value, which directly impacts on their pricing and reimbursement by the various national healthcare systems.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 50 条
  • [1] PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing
    L Rogers, Sara
    Keeling, Nicholas J.
    Giri, Jyothsna
    Gonzaludo, Nina
    Jones, J. Shawn
    Glogowski, Emily
    Formea, Christine M.
    PHARMACOGENOMICS, 2020, 21 (11) : 785 - 796
  • [2] Challenges in the Development and Reimbursement of Personalized Medicine-Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
    Faulkner, Eric
    Annemans, Leven
    Garrison, Lou
    Helfand, Mark
    Holtorf, Anke-Peggy
    Hornberger, John
    Hughes, Dyfrig
    Li, Tracy
    Malone, Daniel
    Payne, Katherine
    Siebert, Uwe
    Towse, Adrian
    Veenstra, David
    Watkins, John
    VALUE IN HEALTH, 2012, 15 (08) : 1162 - 1171
  • [3] The role of informatics in patient-centered care and personalized medicine
    Hanna, Matthew G.
    Pantanowitz, Liron
    CANCER CYTOPATHOLOGY, 2017, 125 : 494 - 501
  • [4] The "We" in the "Me": Solidarity and Health Care in the Era of Personalized Medicine
    Prainsack, Barbara
    SCIENCE TECHNOLOGY & HUMAN VALUES, 2018, 43 (01) : 21 - 44
  • [5] Personalized medicine and preventive health care: juxtaposing health policy and clinical practice
    Gjodsbol, Iben Mundbjerg
    Winkel, Bo Gregers
    Bundgaard, Henning
    CRITICAL PUBLIC HEALTH, 2021, 31 (03) : 327 - 337
  • [6] Health Information Technologies for Cancer Care: Characterizing Developments for Precision and Personalized Medicine
    Shah, Parth V.
    Ringland, Kathryn E.
    CONFERENCE COMPANION PUBLICATION OF THE 2019 COMPUTER SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING (CSCW'19 COMPANION), 2019, : 362 - 366
  • [7] Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report
    Devanathan, Reka
    Alladi, Charanraj Goud
    Ravichandran, Mirunalini
    Ramasamy, Kesavan
    Uppugunduri, Chakradhara Rao S.
    PHARMACOGENOMICS, 2023, 24 (03) : 123 - 129
  • [8] Personalized medicine: importance of clinical interpretative skills for real-world patient care
    Gryn, Steven E.
    Kim, Richard B.
    PERSONALIZED MEDICINE, 2014, 11 (04) : 395 - 408
  • [9] Problems and methods in health care economics: is personalized medicine an exception?
    Sickinger, Sabine
    Payne, Katherine
    Rogowski, Wolf
    ETHIK IN DER MEDIZIN, 2013, 25 (03) : 267 - 275
  • [10] Personalized medicine and access to health care: potential for inequitable access?
    Kelly A McClellan
    Denise Avard
    Jacques Simard
    Bartha M Knoppers
    European Journal of Human Genetics, 2013, 21 : 143 - 147